title: Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
authors.affiliation: Institut für Immunologie, Klinikum Steglitz, Freie Universität, Berlin, F.R.G.
authors.forename: T
authors.initials: T
authors.lastname: Diamantstein
authors.forename: A
authors.initials: A
authors.lastname: Mouzaki
authors.forename: H
authors.initials: H
authors.lastname: Osawa
authors.forename: H D
authors.initials: HD
authors.lastname: Volk
authors.forename: H J
authors.initials: HJ
authors.lastname: Hahn
authors.forename: R L
authors.initials: RL
authors.lastname: Kirkman
authors.forename: T B
authors.initials: TB
authors.lastname: Strom
authors.forename: N L
authors.initials: NL
authors.lastname: Tilney
authors.forename: J W
authors.initials: JW
authors.lastname: Kupiec-Weglinski
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004357:Drug Synergism; D006084:Graft Rejection; D006087:Graft vs Host Reaction; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007376:Interleukin-2; D015375:Receptors, Interleukin-2